ATLANTA — Tests of the first two oral drugs developed for treating multiple sclerosis show that both cut the frequency of relapses and may slow progression of the disease, but with side effects that ...
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
Evogene and Unravel Biosciences are collaborating to use AI to speed the development of therapies that promote myelin sheath ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback